---
document_datetime: 2025-12-29 12:36:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/atripla.html
document_name: atripla.html
version: success
processing_time: 0.1052996
conversion_datetime: 2025-12-29 21:24:44.461579
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Atripla

[RSS](/en/individual-human-medicine.xml/66989)

##### Withdrawn

This medicine's authorisation has been withdrawn

efavirenz / emtricitabine / tenofovir disoproxil Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Atripla](#news-on)
- [More information on Atripla](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 15 November 2021, the European Commission withdrew the marketing authorisation for Atripla (efavirenz / emtricitabine / tenofovir disoproxil) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Gilead Sciences Ireland UC, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Atripla was granted marketing authorisation in the EU on 13 December 2007 for treatment of HIV-1 infection. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2012.

The European Public Assessment Report (EPAR) for Atripla is updated to indicate that the marketing authorisation is no longer valid.

Atripla : EPAR - Medicine overview

English (EN) (675 KB - PDF)

**First published:** 21/10/2009

**Last updated:** 21/01/2022

[View](/en/documents/overview/atripla-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-972)

български (BG) (770.35 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/bg/documents/overview/atripla-epar-medicine-overview_bg.pdf)

español (ES) (673.98 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/es/documents/overview/atripla-epar-medicine-overview_es.pdf)

čeština (CS) (750.55 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/cs/documents/overview/atripla-epar-medicine-overview_cs.pdf)

dansk (DA) (671.07 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/da/documents/overview/atripla-epar-medicine-overview_da.pdf)

Deutsch (DE) (676.01 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/de/documents/overview/atripla-epar-medicine-overview_de.pdf)

eesti keel (ET) (670.98 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/et/documents/overview/atripla-epar-medicine-overview_et.pdf)

ελληνικά (EL) (783.89 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/el/documents/overview/atripla-epar-medicine-overview_el.pdf)

français (FR) (674.79 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/fr/documents/overview/atripla-epar-medicine-overview_fr.pdf)

hrvatski (HR) (696.47 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/hr/documents/overview/atripla-epar-medicine-overview_hr.pdf)

italiano (IT) (672.37 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/it/documents/overview/atripla-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (751.81 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/lv/documents/overview/atripla-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (700.68 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/lt/documents/overview/atripla-epar-medicine-overview_lt.pdf)

magyar (HU) (743.37 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/hu/documents/overview/atripla-epar-medicine-overview_hu.pdf)

Malti (MT) (763.49 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/mt/documents/overview/atripla-epar-medicine-overview_mt.pdf)

Nederlands (NL) (672.63 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/nl/documents/overview/atripla-epar-medicine-overview_nl.pdf)

polski (PL) (748.58 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/pl/documents/overview/atripla-epar-medicine-overview_pl.pdf)

português (PT) (673.76 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/pt/documents/overview/atripla-epar-medicine-overview_pt.pdf)

română (RO) (708.44 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/ro/documents/overview/atripla-epar-medicine-overview_ro.pdf)

slovenčina (SK) (749.04 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/sk/documents/overview/atripla-epar-medicine-overview_sk.pdf)

slovenščina (SL) (738.12 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/sl/documents/overview/atripla-epar-medicine-overview_sl.pdf)

Suomi (FI) (671.48 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/fi/documents/overview/atripla-epar-medicine-overview_fi.pdf)

svenska (SV) (672.45 KB - PDF)

**First published:**

21/10/2009

**Last updated:**

21/01/2022

[View](/sv/documents/overview/atripla-epar-medicine-overview_sv.pdf)

Atripla : EPAR - Risk-management-plan summary

English (EN) (865.7 KB - PDF)

**First published:** 14/05/2019

**Last updated:** 21/01/2022

[View](/en/documents/rmp-summary/atripla-epar-risk-management-plan-summary_en.pdf)

## Product information

Atripla : EPAR - Product Information

English (EN) (1.71 MB - PDF)

**First published:** 13/10/2009

**Last updated:** 21/01/2022

[View](/en/documents/product-information/atripla-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-650)

български (BG) (3.51 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/bg/documents/product-information/atripla-epar-product-information_bg.pdf)

español (ES) (1.7 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/es/documents/product-information/atripla-epar-product-information_es.pdf)

čeština (CS) (3.23 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/cs/documents/product-information/atripla-epar-product-information_cs.pdf)

dansk (DA) (1.64 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/da/documents/product-information/atripla-epar-product-information_da.pdf)

Deutsch (DE) (2.1 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/de/documents/product-information/atripla-epar-product-information_de.pdf)

eesti keel (ET) (1.76 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/et/documents/product-information/atripla-epar-product-information_et.pdf)

ελληνικά (EL) (3.57 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/el/documents/product-information/atripla-epar-product-information_el.pdf)

français (FR) (1.83 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/fr/documents/product-information/atripla-epar-product-information_fr.pdf)

hrvatski (HR) (2.15 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/hr/documents/product-information/atripla-epar-product-information_hr.pdf)

íslenska (IS) (1.69 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/is/documents/product-information/atripla-epar-product-information_is.pdf)

italiano (IT) (2.05 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/it/documents/product-information/atripla-epar-product-information_it.pdf)

latviešu valoda (LV) (3.22 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/lv/documents/product-information/atripla-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.18 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/lt/documents/product-information/atripla-epar-product-information_lt.pdf)

magyar (HU) (3.24 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/hu/documents/product-information/atripla-epar-product-information_hu.pdf)

Malti (MT) (2.94 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/mt/documents/product-information/atripla-epar-product-information_mt.pdf)

Nederlands (NL) (1.68 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/nl/documents/product-information/atripla-epar-product-information_nl.pdf)

norsk (NO) (1.64 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/no/documents/product-information/atripla-epar-product-information_no.pdf)

polski (PL) (3.4 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/pl/documents/product-information/atripla-epar-product-information_pl.pdf)

português (PT) (1.69 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/pt/documents/product-information/atripla-epar-product-information_pt.pdf)

română (RO) (2.24 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/ro/documents/product-information/atripla-epar-product-information_ro.pdf)

slovenčina (SK) (2.87 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/sk/documents/product-information/atripla-epar-product-information_sk.pdf)

slovenščina (SL) (2.79 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/sl/documents/product-information/atripla-epar-product-information_sl.pdf)

Suomi (FI) (1.71 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/fi/documents/product-information/atripla-epar-product-information_fi.pdf)

svenska (SV) (2.03 MB - PDF)

**First published:**

13/10/2009

**Last updated:**

21/01/2022

[View](/sv/documents/product-information/atripla-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0150 17/08/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Atripla : EPAR - All Authorised presentations

English (EN) (591.39 KB - PDF)

**First published:** 07/07/2008

**Last updated:** 21/01/2022

[View](/en/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-506)

български (BG) (701.62 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/bg/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_bg.pdf)

español (ES) (572.81 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/es/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_es.pdf)

čeština (CS) (693.42 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/cs/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (590.28 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/da/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (588 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/de/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (586.75 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/et/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (696.69 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/el/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_el.pdf)

français (FR) (588.39 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/fr/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (586.33 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/is/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_is.pdf)

italiano (IT) (588.19 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/it/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (692.01 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/lv/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (677.27 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/lt/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (688.28 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/hu/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (691.58 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/mt/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (587.92 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/nl/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (587.45 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/no/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_no.pdf)

polski (PL) (642.79 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/pl/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_pl.pdf)

português (PT) (587.75 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/pt/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_pt.pdf)

română (RO) (674.23 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/ro/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (689.38 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/sk/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (648.39 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/sl/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (587.69 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/fi/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (587.36 KB - PDF)

**First published:**

07/07/2008

**Last updated:**

21/01/2022

[View](/sv/documents/all-authorised-presentations/atripla-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Atripla Active substance

- efavirenz
- emtricitabine
- tenofovir disoproxil fumarate

International non-proprietary name (INN) or common name

- efavirenz
- emtricitabine
- tenofovir disoproxil

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR06

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of &lt; 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Atripla prior to initiation of their first antiretroviral treatment regimen.

The demonstration of the benefit of Atripla is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to Atripla.

No data are currently available from clinical studies with Atripla in treatment-naive or in heavily pretreated patients.

No data are available to support the combination of Atripla and other antiretroviral agents.

## Authorisation details

EMA product number EMEA/H/C/000797 Marketing authorisation holder

Gilead Sciences Ireland UC

IDA Business &amp; Technology Park

Marketing authorisation issued 13/12/2007 Revision 36

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Atripla : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.33 MB - PDF)

**First published:** 13/10/2009

**Last updated:** 21/01/2022

[View](/en/documents/procedural-steps-after/atripla-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Atripla : EPAR - Scientific Discussion

English (EN) (1.12 MB - PDF)

**First published:** 18/12/2007

**Last updated:** 21/01/2022

[View](/en/documents/scientific-discussion/atripla-epar-scientific-discussion_en.pdf)

Atripla : EPAR - Procedural steps taken before authorisation

English (EN) (609.57 KB - PDF)

**First published:** 18/12/2007

**Last updated:** 21/01/2022

[View](/en/documents/procedural-steps/atripla-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Atripla

[Updated advice on body fat changes and lactic acidosis with HIV medicines](/en/news/updated-advice-body-fat-changes-lactic-acidosis-hiv-medicines) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

#### More information on Atripla

- [Impact of single tablet regimens on adherence and prescription errors? How big an issue and how relevant in both clinical and economic terms (iSTRAP) - post-authorisation study](https://catalogues.ema.europa.eu/study/19193)

**This page was last updated on** 21/01/2022

## Share this page

[Back to top](#main-content)